What is the share price of Gennex Laboratories Ltd (GENNEX) today?
The share price of GENNEX as on 9th July 2025 is ₹13.11. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Gennex Laboratories Ltd (GENNEX) share?
The past returns of Gennex Laboratories Ltd (GENNEX) share are- Past 1 week: 0.81%
- Past 1 month: -5.11%
- Past 3 months: -1.84%
- Past 6 months: -26.98%
- Past 1 year: -13.28%
- Past 3 years: 101.57%
- Past 5 years: 181.32%
What are the peers or stocks similar to Gennex Laboratories Ltd (GENNEX)?
The peers or stocks similar to Gennex Laboratories Ltd (GENNEX) include:What is the market cap of Gennex Laboratories Ltd (GENNEX) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Gennex Laboratories Ltd (GENNEX) is ₹291.13 Cr as of 9th July 2025.What is the 52 week high and low of Gennex Laboratories Ltd (GENNEX) share?
The 52-week high of Gennex Laboratories Ltd (GENNEX) is ₹29 and the 52-week low is ₹11.15.What is the PE and PB ratio of Gennex Laboratories Ltd (GENNEX) stock?
The P/E (price-to-earnings) ratio of Gennex Laboratories Ltd (GENNEX) is 18.06. The P/B (price-to-book) ratio is 1.65.Which sector does Gennex Laboratories Ltd (GENNEX) belong to?
Gennex Laboratories Ltd (GENNEX) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Gennex Laboratories Ltd (GENNEX) shares?
You can directly buy Gennex Laboratories Ltd (GENNEX) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Gennex Laboratories Ltd
GENNEX Share Price
13.112.42% (+0.31)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
GENNEX Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
GENNEX Performance & Key Metrics
GENNEX Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 17.68 | 1.65 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.69 | 6.41 | 0.79% |
GENNEX Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
GENNEX Company Profile
Gennex Laboratories Limited is engaged in manufacturing of bulk drugs, intermediates and biotech products. Its product portfolio is spread over various product segments encompassing expectorants, muscle relaxants, analgesic and anti-fungal.
SUNPHARMA
PE Ratio
36.72
36.72
1Y Return
7.46%
7.46%
Buy Reco %
87.50
87.50
CIPLA
PE Ratio
22.80
22.80
1Y Return
0.08%
0.08%
Buy Reco %
73.33
73.33
TORNTPHARM
PE Ratio
58.83
58.83
1Y Return
15.25%
15.25%
Buy Reco %
70.83
70.83
DRREDDY
PE Ratio
18.89
18.89
1Y Return
1.76%
1.76%
Buy Reco %
55.17
55.17
MANKIND
PE Ratio
50.40
50.40
1Y Return
17.92%
17.92%
Buy Reco %
81.25
81.25
GENNEX Forecast
GENNEX Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
GENNEX
GENNEX
Income
Balance Sheet
Cash Flow
Annual Normal View
GENNEX Income Statement
GENNEX Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 42.03 | 44.69 | 56.58 | 56.68 | 60.17 | 62.59 | 69.56 | 91.62 | 148.33 | 148.34 | ||||||||||
Raw Materials | 24.41 | 26.88 | 36.31 | 36.20 | 35.18 | 41.23 | 48.14 | 58.98 | 121.19 | 121.18 | ||||||||||
| Power & Fuel Cost | 1.97 | 2.26 | 2.85 | 3.30 | 3.01 | 3.17 | 4.39 | 4.67 | ||||||||||||
| Employee Cost | 4.96 | 5.55 | 6.12 | 6.81 | 7.21 | 6.97 | 7.87 | 7.79 | ||||||||||||
| Selling & Administrative Expenses | 3.13 | 3.01 | 4.23 | 3.34 | 3.44 | 3.43 | 4.42 | 3.29 | ||||||||||||
| Operating & Other expenses | 2.92 | 3.88 | 2.27 | 2.72 | 4.65 | 1.03 | -3.91 | -5.05 | ||||||||||||
EBITDA | 4.64 | 3.11 | 4.80 | 4.31 | 6.68 | 6.76 | 8.65 | 21.94 | 27.14 | 27.16 | ||||||||||
| Depreciation/Amortization | 0.84 | 0.92 | 0.98 | 1.00 | 0.88 | 0.79 | 0.92 | 2.37 | 1.99 | 2.60 | ||||||||||
| PBIT | 3.80 | 2.19 | 3.82 | 3.31 | 5.80 | 5.97 | 7.73 | 19.57 | 25.15 | 24.56 | ||||||||||
| Interest & Other Items | 0.71 | 0.73 | 0.79 | 0.75 | 0.74 | 0.88 | 1.35 | 3.08 | 3.61 | 2.99 | ||||||||||
| PBT | 3.09 | 1.46 | 3.03 | 2.56 | 5.06 | 5.09 | 6.38 | 16.49 | 21.54 | 21.57 | ||||||||||
| Taxes & Other Items | 0.40 | 0.62 | 0.80 | 0.69 | 1.02 | 1.17 | 1.45 | 3.32 | 5.42 | 5.10 | ||||||||||
| Net Income | 2.69 | 0.84 | 2.23 | 1.87 | 4.04 | 3.92 | 4.93 | 13.17 | 16.12 | 16.47 | ||||||||||
| EPS | 0.20 | 0.06 | 0.17 | 0.14 | 0.30 | 0.30 | 0.32 | 0.65 | 0.80 | 0.72 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
GENNEX Company Updates
GENNEX Stock Peers
GENNEX Past Performance & Peer Comparison
GENNEX Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Gennex Laboratories Ltd | 18.06 | 1.65 | — |
| Sun Pharmaceutical Industries Ltd | 36.72 | 5.54 | 0.96% |
| Cipla Ltd | 22.80 | 3.84 | 1.07% |
| Torrent Pharmaceuticals Ltd | 58.83 | 14.81 | 0.18% |
GENNEX Stock Price Comparison
Compare GENNEX with any stock or ETFCompare GENNEX with any stock or ETF
GENNEX
GENNEX Holdings
GENNEX Shareholdings
GENNEX Promoter Holdings Trend
GENNEX Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
GENNEX Institutional Holdings Trend
GENNEX Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
GENNEX Shareholding Pattern
GENNEX Shareholding Pattern
GENNEX Shareholding History
GENNEX Shareholding History
Foreign Institutions
smallcases containing GENNEX stock
smallcases containing GENNEX stock
Looks like this stock is not in any smallcase yet.
GENNEX Events
GENNEX Events
GENNEX Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
GENNEX has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
GENNEX Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
GENNEX has not given any dividends in last 5 years
GENNEX Dividends
GENNEX Dividends
Hmm, looks like data is unavailable here. Please come back after some timeGENNEX Stock News & Opinions
GENNEX Stock News & Opinions
Articles & Videos
Earnings
Gennex Laboratories consolidated net profit declines 48.44% in the March 2025 quarter
Net profit of Gennex Laboratories declined 48.44% to Rs 2.32 crore in the quarter ended March 2025 as against Rs 4.50 crore during the previous quarter ended March 2024. Sales rose 20.39% to Rs 40.33 crore in the quarter ended March 2025 as against Rs 33.50 crore during the previous quarter ended March 2024. For the full year,net profit rose 30.84% to Rs 16.12 crore in the year ended March 2025 as against Rs 12.32 crore during the previous year ended March 2024. Sales rose 59.04% to Rs 137.90 crore in the year ended March 2025 as against Rs 86.71 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales40.3333.50 20 137.9086.71 59 OPM %14.5118.72 -19.6925.30 - PBDT4.655.53 -16 23.5418.86 25 PBT4.105.30 -23 21.5516.49 31 NP2.324.50 -48 16.1212.32 31 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Gennex Laboratories to discuss results
Gennex Laboratories will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Gennex Laboratories consolidated net profit rises 79.15% in the December 2024 quarter
Net profit of Gennex Laboratories rose 79.15% to Rs 4.64 crore in the quarter ended December 2024 as against Rs 2.59 crore during the previous quarter ended December 2023. Sales rose 97.02% to Rs 37.71 crore in the quarter ended December 2024 as against Rs 19.14 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales37.7119.14 97 OPM %18.9625.08 - PBDT6.313.97 59 PBT5.823.52 65 NP4.642.59 79 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Gennex Laboratories to hold board meeting
Gennex Laboratories will hold a meeting of the Board of Directors of the Company on 14 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Gennex Laboratories standalone net profit rises 56.39% in the September 2024 quarter
Net profit of Gennex Laboratories rose 56.39% to Rs 4.16 crore in the quarter ended September 2024 as against Rs 2.66 crore during the previous quarter ended September 2023. Sales rose 73.38% to Rs 24.69 crore in the quarter ended September 2024 as against Rs 14.24 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales24.6914.24 73 OPM %15.0327.88 - PBDT5.483.75 46 PBT5.013.55 41 NP4.162.66 56 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Gennex Laboratories schedules board meeting
Gennex Laboratories will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Gennex Laboratories AGM scheduled
Gennex Laboratories announced that the 39th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Corporate
Gennex Laboratories to hold board meeting
Gennex Laboratories will hold a meeting of the Board of Directors of the Company on 6 September 2024.Powered by Capital Market - Live
10 months agoCapital Market - Live
Earnings
Gennex Laboratories consolidated net profit rises 63.51% in the June 2024 quarter
Net profit of Gennex Laboratories rose 63.51% to Rs 4.66 crore in the quarter ended June 2024 as against Rs 2.85 crore during the previous quarter ended June 2023. Sales rose 71.74% to Rs 28.32 crore in the quarter ended June 2024 as against Rs 16.49 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales28.3216.49 72 OPM %23.6230.93 - PBDT5.964.37 36 PBT5.513.72 48 NP4.662.85 64 Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Gennex Laboratories to discuss results
Gennex Laboratories will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live
11 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 21.22%, vs industry avg of 10.1%
Over the last 5 years, market share increased from 0.02% to 0.04%
Over the last 5 years, net income has grown at a yearly rate of 53.85%, vs industry avg of 20.04%